Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
25 hedge funds and large institutions have $383K invested in Navidea Biopharmaceuticals Inc. in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
4% less funds holding
Funds holding: 26 → 25 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
65% less capital invested
Capital invested by funds: $1.08M → $383K (-$696K)
73% less call options, than puts
Call options by funds: $14K | Put options by funds: $52K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$18.7K |
| 2 |
VF
Virtu Financial
New York
|
+$17.8K |
| 3 |
Renaissance Technologies
New York
|
+$6.16K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$5.18K |
| 5 |
ACM
Allred Capital Management
Dallas,
Texas
|
+$4.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$17.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$10K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$4.94K |
NAVB Hedge Fund Activity: Q3 2022 in Review
25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2022, worth a combined $383K — down 65% from $1.08M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NAVB and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $18.7K. The largest seller was Group One Trading, cutting an estimated $17.1K.
- 25 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2022, down from 26 in Q2 2022.
- Funds reported $383K of Navidea Biopharmaceuticals Inc. stock for Q3 2022, down 65% quarter-over-quarter.
- 3 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2022 and 4 closed out, a net change of -1 holder.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2022 was Millennium Management, an estimated $18.7K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2022 was Group One Trading, an estimated $17.1K sold.
Based on aggregated 13F filings for Q3 2022.